PMID- 33253313
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20210105
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 11
DP  - 2020
TI  - Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review 
      and meta-analysis.
PG  - e0242982
LID - 10.1371/journal.pone.0242982 [doi]
LID - e0242982
AB  - OBJECTIVE: To assess the efficacy and toxicity of anlotinib for the treatment of 
      refractory advanced non-small-cell lung cancer (NSCLC). METHODS: We 
      systematically searched databases for randomized controlled trials on anlotinib 
      treatment for patients with advanced NSCLC published until November 6, 2020. 
      Articles were assessed and data were extracted independently by two 
      investigators. Further, we analyzed hazard ratios (HRs) for progression-free and 
      overall survival (PFS and OS, respectively). In addition, we analyzed risk ratio 
      (RR) for overall response and disease control rates (ORR and DCR, respectively) 
      and the odds ratio (OR) for the main adverse events (AEs) using RevMan 5.3 
      software. RESULTS: This analysis included 594 patients from three clinical 
      studies. The pooled HRs for PFS and OS were 0.27 (95% confidence interval (CI): 
      0.22-0.33, P < 0.001) and 0.68 (95% CI: 0.56-0.83, P < 0.001), respectively, 
      indicating that anlotinib administration significantly improved PFS and OS in 
      patients with advanced NSCLC. The pooled RRs for ORR and DCR were 11.62 (95% CI: 
      2.75-49.14, P < 0.001) and 2.30 (95% CI: 1.91-2.77, P < 0.001), respectively, 
      indicating that anlotinib administration in patients with advanced NSCLC improved 
      ORR and DCR. The pooled OR for AEs of grade 3 or higher was 2.94 (95% CI: 
      1.99-4.35, P < 0.001), indicating that AEs of grade 3 or higher were more 
      prevalent in the anlotinib group than in the placebo group. CONCLUSION: 
      Anlotinib, an effective choice of third- or later line therapy for patients with 
      refractory advanced NSCLC, provides clinical benefits in terms of PFS, OS, ORR, 
      and DCR. AEs associated with anlotinib were tolerable.
FAU - Yu, Guocan
AU  - Yu G
AD  - Department of thoracic surgery, Zhejiang Chinese Medicine and Western Medicine 
      Integrated Hospital, Hangzhou, Zhejiang, China.
FAU - Shen, Yanqin
AU  - Shen Y
AD  - Department of tuberculosis, Zhejiang Chinese Medicine and Western Medicine 
      Integrated Hospital, Hangzhou, Zhejiang, China.
FAU - Xu, Xudong
AU  - Xu X
AD  - Department of thoracic surgery, Zhejiang Chinese Medicine and Western Medicine 
      Integrated Hospital, Hangzhou, Zhejiang, China.
FAU - Zhong, Fangming
AU  - Zhong F
AUID- ORCID: 0000-0001-7093-136X
AD  - Department of thoracic surgery, Zhejiang Chinese Medicine and Western Medicine 
      Integrated Hospital, Hangzhou, Zhejiang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201130
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinolines)
RN  - 0 (anlotinib)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/epidemiology/pathology
MH  - Disease Progression
MH  - Humans
MH  - Indoles/adverse effects/*therapeutic use
MH  - Progression-Free Survival
MH  - Proportional Hazards Models
MH  - Protein Kinase Inhibitors/adverse effects/*therapeutic use
MH  - Quinolines/adverse effects/*therapeutic use
MH  - Treatment Outcome
PMC - PMC7703897
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/01 06:00
MHDA- 2021/01/06 06:00
PMCR- 2020/11/30
CRDT- 2020/11/30 17:13
PHST- 2020/09/07 00:00 [received]
PHST- 2020/11/12 00:00 [accepted]
PHST- 2020/11/30 17:13 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
PHST- 2020/11/30 00:00 [pmc-release]
AID - PONE-D-20-28108 [pii]
AID - 10.1371/journal.pone.0242982 [doi]
PST - epublish
SO  - PLoS One. 2020 Nov 30;15(11):e0242982. doi: 10.1371/journal.pone.0242982. 
      eCollection 2020.